Article Text

Download PDFPDF
Chronic inflammatory demyelinating polyneuropathy during treatment with interferon-α
  1. Mª EUGENIA MARZO,
  2. MAR TINTORÉ,
  3. ORIOL FABREGUES,
  4. XAVIER MONTALBÁN,
  5. AGUSTÍN CODINA
  1. Unit of Clinical Neuroimmunology, Department of Neurology, Hospital Vall d’Hebron, Barcelona, Spain
  1. Dr Xavier Montalban, Unit of Clinical Neuroimmunology, Department of Neurology, Hospital Vall d’Hebron, Psg Vall d’Hebron 119–129, Barcelona 08915, Spain. Fax 0034 3 4274700; email xmontal{at}ar.vhebron.es

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Interferon-α (IFN-α) is widely used for the treatment of chronic viral hepatitis. There have been some reports concerning the development of autoimmune diseases, particularly thyroid disease, in patients under treatment with IFN.1 Disorders including autoimmune haemolytic anaemia, pernicious anaemia, thrombocytopenic purpura, systemic lupus erythematosus, Raynaud′s disease, parotiditis, and epididymitis have been reported. Some neurological problems have also been described2; although most such adverse events have involved the CNS, several cases of peripheral nervous system involvement have been reported—namely, axonal polyneuropathy,3 neuralgic amyotrophy, multiple mononeuropathies, and myasthenia gravis.4 On the other hand, some authors have reported that IFN-α may be an effective alternative therapy in patients with chronic inflammatory demyelinating polyneuropathy …

View Full Text